SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED

Shandong Xinhua Pharmaceutical Company Limited

719 CNE100000411

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:49 2024-05-06 am EDT			5-day change	1st Jan Change
5.55 ^HKD	+2.02%		+1.83%	-3.98%

Apr. 25	Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 11	Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation	MT

Shandong Xinhua Pharmaceutical Company Limited announced that it has received CNY 249.999999 million in funding from Hualu Investment Development Co., Ltd.

March 27, 2022

On March 28, 2022, Shandong Xinhua Pharmaceutical Company Limited closed the transaction. The company has received gross proceeds of CNY 249,999,999 in the transaction. The company has paid issuance expenses of CNY 5,633,588.91 and received net proceeds of CNY 244,366,410 of which, CNY 37,091,988 included in share capital and CNY 207,274,422.21 into capital reserve.

Post the transaction, Hualu Investment Development Co., Ltd. will own 41,235,156 shares in the company, accounting for 6.16% stake.

Latest news about Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation	Apr. 11	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application	Apr. 08	CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit	Mar. 29	MT
Shandong Xinhua Pharmaceutical Proposes New Auditor	Mar. 28	MT
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023	Mar. 28	CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Xinhua Pharma's Ibuprofen Gets Registration Approval in China	Mar. 13	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient	Feb. 28	CI
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate	Jan. 19	CI
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes	Dec. 25	CI
Shandong Xinhua Pharmaceutical Gets Certificate for Registration of Levamlodiping Besylate Tablets	Dec. 13	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)	Dec. 13	CI
Respiratory Drug by Xinhua Pharmaceutical Unit Passes Regulatory Evaluation for Generic Drugs in China	Dec. 04	MT
Xinhua Pharmaceutical's Nine-Month Profit Jumps 34%	23-10-30	MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Shandong Xinhua Pharmaceutical’s AntiCoagulant Tablets Get Drug Registration Certificate	23-10-18	MT
China Grants Marketing Approval for Shandong Xinhua Pharmaceutical's Uric Acid Medication; Shares Rise 4%	23-10-11	MT
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat	23-10-10	CI
Xinhua Pharmaceutical Unit's Clarithromycin Granules Passes Regulatory Evaluation	23-09-20	MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration	23-08-11	CI
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee	23-07-26	CI
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023	23-07-19	CI
Shandong’s 20MG Ulcer Drug Passes Efficacy Audit	23-07-17	MT

Chart Shandong Xinhua Pharmaceutical Company Limited

Duration

Period

Chart Shandong Xinhua Pharmaceutical Company Limited

More charts

Company Profile

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Companyâs main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED	-3.98%	1.22B
ELI LILLY AND COMPANY	+31.52%	662B
NOVO NORDISK A/S	+21.96%	546B
JOHNSON & JOHNSON	-5.21%	359B
MERCK & CO., INC.	+17.02%	323B
ABBVIE INC.	+5.01%	289B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.81%	198B
ROCHE HOLDING AG	-10.63%	194B
AMGEN INC.	+3.98%	167B

Other Pharmaceuticals